AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 281 min read$GKOS

Glaukos (NYSE: GKOS) insider eyes multimillion-dollar stock sale

Glaukos (GKOS) officer Tomas Navratil filed a notice to sell 13,744 shares, valued at $2.48 million, under Rule 144. This follows prior sales of 1,537 and 716 shares in June and July 2026, respectively.

Original reporting
stocktitan.net
Published Aug 28, 2026, 5:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The disclosed sale adds a modest amount of potential supply, which could modestly depress the stock if executed quickly.

02

Market read

A small insider sale that may cause slight short‑term price pressure but is unlikely to move the market.

03

What to watch

If the insider holds additional unreported positions, future sales could accumulate, but current filing is isolated.

Relevance 4/10Novelty 4/10Timing: as of Aug 28 2026 (same‑day filing)

Background

Form 144 filings disclose planned sales of restricted or insider‑held shares under SEC rules.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Officer Tomas Navratil filed a Form 144 to sell 13,744 shares worth $2.48 M, indicating potential new supply of GKOS stock.

Expected impact

Minor downward pressure; price may dip slightly if shares hit the market.

Evidence & confidence

A $2.5 M insider sale represents a small fraction of the 59 M shares outstanding, so impact is limited.

Market effects

Sector

Minimal; the filing does not affect the broader ophthalmic device sector.

Regional

None; the news is company‑specific.

Global

Low; limited to GKOS investors.

Counterpoint

What could challenge this read

The sale may be a routine liquidity move and not a bearish signal; price could remain stable.

Key entities

  • Officer
    Tomas Navratil

    Insider filing a Rule 144 sale of GKOS shares.

Read at source← All news

Related articles

AUG 25
$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

ocbj.com2 min
AUG 20
$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

tradingview.com2 min
AUG 20
$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

investing.com2 min
AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min
JUL 30
$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min